Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
AURORA-HFpEF
A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
3 other identifiers
interventional
208
11 countries
117
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 heart-failure
Started Nov 2023
Typical duration for phase_2 heart-failure
117 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2023
CompletedStudy Start
First participant enrolled
November 7, 2023
CompletedFirst Posted
Study publicly available on registry
November 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 3, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 3, 2026
December 15, 2025
December 1, 2025
2.7 years
November 3, 2023
December 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Incidence of treatment emergent adverse events (TEAEs)
Up to approximately 24 weeks
Incidence of serious adverse events (SAEs)
Up to approximately 24 weeks
Incidence of AEs leading to treatment discontinuation
Up to approximately 20 weeks
Secondary Outcomes (1)
Summary of plasma concentrations of MYK-224
Up to approximately 20 weeks
Study Arms (2)
BMS-986435
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
You may not qualify if:
- Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (117)
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Colorado Heart and Vascular - Lakewood
Lakewood, Colorado, 80228-1710, United States
Ascension St. Vincent's Riverside Hospital - PPDS
Jacksonville, Florida, 32204-4748, United States
Local Institution - 0003
Miami, Florida, 33133-4223, United States
University of Miami FL Miller School of Medicine -1120 NW 14th St
Miami, Florida, 33136-2107, United States
Local Institution - 0014
Atlanta, Georgia, 30322-1013, United States
Local Institution - 0048
Atlanta, Georgia, 30322-1013, United States
Bluhm Cardiovascular Institute of Northwestern
Chicago, Illinois, 60611-5969, United States
Chicago Medical Research, LLC - Hazel Crest
Hazel Crest, Illinois, 60429-2196, United States
Ascension Medical Group St. Vincent - Indianapolis Heart Care
Indianapolis, Indiana, 46260-1992, United States
Local Institution - 0045
Indianapolis, Indiana, 46260-1992, United States
St. Louis Heart and Vascular
St Louis, Missouri, 63136-6111, United States
Local Institution - 0043
St Louis, Missouri, 63136, United States
Local Institution - 0117
Hackensack, New Jersey, 07601, United States
Capital Cardiology Associates
Albany, New York, 12211, United States
Local Institution - 0105
Brooklyn, New York, 11215, United States
Weill Cornell Medicine
New York, New York, 10065-4805, United States
University of Rochester Medical Center - PPDS
Rochester, New York, 14618-2668, United States
Rochester General Hospital Center for Clinical Research
Rochester, New York, 14621, United States
Laurelton Heart Specialist PC - MyClinical - PPDS
Rosedale, New York, 11422-1320, United States
Duke Cardiology Clinic - PPDS
Durham, North Carolina, 27710-4000, United States
Local Institution - 0058
Cincinnati, Ohio, 45242, United States
Local Institution - 0041
Oklahoma City, Oklahoma, 73135-2607, United States
South Oklahoma Heart Research
Oklahoma City, Oklahoma, 73135-2607, United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001, United States
Tennessee Center for Clinical Trials
Tullahoma, Tennessee, 37388-8260, United States
Local Institution - 0104
Austin, Texas, 78756-4080, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Angiocardiac Care of Texas - PA - PPDS
Houston, Texas, 77025-5253, United States
Local Institution - 0051
Houston, Texas, 77025-5253, United States
Local Institution - 0066
Falls Church, Virginia, 22042-1262, United States
Corporación Médica de General San Martín
Ciudad del Libertador General San Martín, Buenos Aires, B1650BNB, Argentina
Local Institution - 0107
Zárate, Buenos Aires, B2800DGH, Argentina
Local Institution - 0115
Zárate, Buenos Aires, B2800DGH, Argentina
Local Institution - 0090
Córdoba, Córdoba Province, X5000AAX, Argentina
Local Institution - 0053
Córdoba, Córdoba Province, X5003DCE, Argentina
Local Institution - 0073
Rosario, Santa Fe Province, S2000DSR, Argentina
IPR-Investigaciones en Patologías Respiratorias
San Miguel de Tucumán, Tucumán Province, T4000IAP, Argentina
Centro de Especialidades Médicas CEMEDIC
Buenos Aires, 1407, Argentina
Local Institution - 0068
Buenos Aires, C1179AAB, Argentina
Local Institution - 0067
Buenos Aires, C1431FWO, Argentina
Sanatorio Duarte Quiros
Córdoba, X5000AOQ, Argentina
Local Institution - 0069
Salta, A4406BPF, Argentina
Centro de Investigaciones Clínicas Del Litoral SRL
Santa Fe, S3000FWO, Argentina
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2, Canada
Medicus MFC Inc.
Toronto, Ontario, M4P 1E4, Canada
Local Institution - 0030
Toronto, Ontario, M5S 1B2, Canada
Local Institution - 0040
Toronto, Ontario, M5S 1B2, Canada
Local Institution - 0011
Montreal, Quebec, H1T 1C8, Canada
Local Institution - 0035
Trois-Rivières, Quebec, G9A 1Y1, Canada
Peking Union Medical College Hospital - East Campus
Beijing, Beijing Municipality, 100730, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Henan Science and Technology University - Jinghua Campus
Luoyang, Henan, 471003, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
The Second Affiliated Hospital, Zhejiang University School of Medicine - Jiefanglu Campus
Hangzhou, Zhejiang, 310009, China
Local Institution - 0109
Jerusalem, Jerusalem, 90000, Israel
Local Institution - 0113
Jerusalem, Jerusalem, 9103102, Israel
Local Institution - 0111
Beersheba, 84101, Israel
Local Institution - 0112
Be’er Ya‘aqov, 7033001, Israel
Local Institution - 0108
Haifa, 3109601, Israel
Local Institution - 0110
Petah Tikva, 49100, Israel
Local Institution - 0106
Rehovot, 76100, Israel
Local Institution - 0116
Safed, 13100, Israel
Local Institution - 0027
Foggia, Apulia, 71100, Italy
Local Institution - 0038
Foggia, Apulia, 71100, Italy
Local Institution - 0019
Naples, Campania, 80131, Italy
Local Institution - 0023
Milan, Lombardy, 20162, Italy
Local Institution - 0033
Milan, Lombardy, 20162, Italy
IRCCS Policlinico San Donato
San Donato Milanese, Lombardy, 20097, Italy
Local Institution - 0050
San Donato Milanese, Lombardy, 20097, Italy
Local Institution - 0052
Massa, Tuscany, 54100, Italy
Local Institution - 0009
Bergamo, 24127, Italy
Local Institution - 0017
Pisa, 56124, Italy
Hyogo Prefectural Harima-Himeji General Medical Center
Himeji-Shi, Hyōgo, 672-8044, Japan
National Hospital Organization Kanazawa Medical Center
Kanazawa, Ishikawa-ken, 920-8650, Japan
Okayama Rosai Hospital
Okayama, Okayama-ken, 702-8055, Japan
Kishiwada Tokushukai Hospital
Kishiwada, Osaka, 596-0042, Japan
Takatsuki Red Cross Hospital
Takatsuki-Shi, Osaka, 569-1045, Japan
Clinical Trials UMED Sp. z o.o.
Lódz, Lódzkie, 92-213, Poland
Local Institution - 0031
Bialystok, Podlaskie Voivodeship, 15-276, Poland
Local Institution - 0044
Bialystok, Podlaskie Voivodeship, 15-276, Poland
Local Institution - 0020
Lublin, Woj. Lubelskie, 20090, Poland
Local Institution - 0049
Lublin, Woj. Lubelskie, 20090, Poland
Local Institution - 0006
Krakow, 30-082, Poland
Local Institution - 0024
Oświęcim, 51162, Poland
Chungnam National University Hospital
Daejeon, Daejeon Gwang'yeogsi, 35015, South Korea
Inha University Hospital
Junggu, Incheon Gwang'yeogsi, 22332, South Korea
Severance Hospital Yonsei University Health System
Seoul, Seoul Teugbyeolsi, 03722, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seoul Teugbyeolsi, 06591, South Korea
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, 6351, South Korea
Pusan National University Hospital
Busan, 49241, South Korea
Keimyung University Dongsan Hospital
Daegu, 42601, South Korea
Chonnam National University Hospital
Gwangju, 61469, South Korea
Seoul National University Bundang Hospital
Seongnam-si, 0, South Korea
Seoul National University Hospital
Seoul, 03080, South Korea
Local Institution - 0012
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Local Institution - 0025
Majadahonda, Madrid, 28222, Spain
Local Institution - 0047
Majadahonda, Madrid, 28222, Spain
Hospital Universitario Virgen de La Arrixaca
El Palmar, Murcia, 30120, Spain
Local Institution - 0039
El Palmar, Murcia, 30120, Spain
Local Institution - 0042
Málaga, Málaga, 29010, Spain
Local Institution - 0026
Madrid, 28034, Spain
Local Institution - 0034
Madrid, 28034, Spain
Local Institution - 0032
Málaga, 29010, Spain
Hospital Nuestra Señora de Valme
Seville, 41014, Spain
Local Institution - 0046
Seville, 41014, Spain
Local Institution - 0010
Valencia, 46010, Spain
Northwick Park Hospital
Harrow, Greater London, HA1 3UJ, United Kingdom
North Tyneside General Hospital
North Shields, Northumberland, NE29 8NH, United Kingdom
Leeds General Infirmary - PPDS
Leeds, Yorkshire, LS1 3EX, United Kingdom
Local Institution - 0057
Sheffield, Yorkshire, S5 7AU, United Kingdom
Bristol Royal Infirmary
Bristol, BS2 8HW, United Kingdom
Local Institution - 0097
Dundee, DD1 9SY, United Kingdom
Local Institution - 0075
London, SE1 7EH, United Kingdom
John Radcliffe Hospital
Oxford, OX3 9DU, United Kingdom
University Hospital of North Tees
Stockton-on-Tees, TS19 8PE, United Kingdom
New Cross Hospital
Wolverhampton, WV10 0QP, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2023
First Posted
November 8, 2023
Study Start
November 7, 2023
Primary Completion (Estimated)
July 3, 2026
Study Completion (Estimated)
July 3, 2026
Last Updated
December 15, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html